Background　Atopic　dermatitis　(AD)　is　a　chronic　inflammatory　skin　condition　that　can　be　particularly　challenging　to　manage　in　older　adults.　Dupilumab,　a　monoclonal　antibody　targeting　the　interleukin-4　receptor　alpha　subunit,　has　shown　promise　in　treating　moderate　to　severe　AD.　However,　its　efficacy　and　safety　in　older　adults　with　refractory　AD　have　not　been　extensively　studied.　Objective　The　objective　of　this　study　is　to　evaluate　the　efficacy　and　safety　of　dupilumab　in　treating　older　adults　with　refractory　atopic　dermatitis　and　to　determine　its　potential　as　a　therapeutic　option　in　this　demographic.　Methods　A　retrospective,　single-center　study　was　conducted　involving　73　older　adults　(aged　＞=　60　years)　with　moderate-to-severe　AD.　The　Eczema　Area　and　Severity　Index　(EASI),　Pruritus　Numerical　Rating　Scales　(P-NRS),　and　Dermatology　Life　Quality　Index　(DLQI)　scores　were　recorded　at　baseline　and　at　weeks　6　and　16.　Adverse　events　(AEs)　were　also　monitored.　Results　Following　dupilumab　treatment,　a　significant　reduction　in　EASI,　P-NRS,　and　DLQI　scores　was　observed　compared　with　baseline　(p　＜　0.0001),　indicating　improved　clinical　symptoms　and　quality　of　life.　Adverse　events　were　mostly　mild　and　did　not　lead　to　treatment　discontinuation.　Conclusions　Dupilumab　demonstrates　significant　efficacy　and　a　favorable　safety　profile　in　managing　refractory　AD　in　older　adults,　suggesting　it　as　a　potential　effective　therapeutic　option　for　this　demographic.